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Background: In chronic obstructive pulmonary disease (COPD) the clinical efficacy of broncho-
dilator therapy delivered via a nebulizer versus an aerochamber on FEV1 is controversial. No
studies comparing changes in inspiratory pulmonary function parameters (ILPs) using these
inhaler devices are currently available. This information might be of interest because due to
dynamic bronchial compression, the relationship between the ILPs and dyspnea is more reli-
able than that between FEV1 and dyspnea. Therefore, our study aimed to investigate whether
changes in ILPs after use of these inhaler devices were similar to the changes in FEV1 and corre-
late with VAS (Visual Analogue Scale).
Methods: Forty-one stable COPD patients participated in a crossover trial. Spirometry was per-
formed before and after two puffs Combivent (200 mcg salbutamol and 20 mcg ipratropium per
puff) using an aerochamber or 2 mL of Combivent (2.5 mg salbutamol and 250 mcg ipratropium
per mL) using a nebulizer. Differences in lung function parameters and changes in VAS were
measured.
Results: ILP values improved significantly from baseline after Combivent administration using
both devices (p  0.004). With both devices, the mean percent changes were significantly
greater for FEV1 than the ILPs (p  0.003), except for IC (p Z 0.19). The mean VAS score
did not differ significantly between the devices (p Z 0.33), but significant correlations were
found between the VAS and forced inspiratory flow at 50% of the vital capacity (FIF50) and peak
inspiratory flow (PIF) when a nebulizer was used. With an aerochamber, no significant2585691; fax: þ31 102585549.
sunilse@hetnet.nl (S.K. Ramlal).
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1394 S.K. Ramlal et al.correlations between lung function parameters and VAS were found.
Conclusions: The present study demonstrates that ILPs improved significantly after using
either device. Although significant correlations were found between the VAS and FIF50 and
PIF for the nebulizer, in stable COPD patients, the pMDI plus spacer is a better route of admin-
istration than a nebulizer.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
In chronic obstructive pulmonary disease (COPD), bron-
chodilator therapy using a dry powder inhaler (DPI) or a
metered-dose inhaler (pMDI) is more convenient and cost
effective than nebulizer therapy.1 The DPI is breath-
activated by inspiration and does not require hand-lung
coordination. However, the pMDI, the most commonly
used device, is technique dependent because the pMDI
requires proper hand-lung coordination. Nebulizers are
used for acute therapy in emergency departments and
hospitals but are also available for home use. For nebu-
lizers, no special timing or coordination is needed, and they
require minimal patient effort. Many studies on broncho-
dilator therapy using a DPI, pMDI with a spacer and nebu-
lizers for treating COPD have concluded that these delivery
devices are equally effective, as measured by changes in
the forced expiratory volume in 1 s (FEV1).
2e7 In contrast,
some studies have shown that nebulizers are superior to
pMDIs based on improvements in spirometric values and
symptoms.8,9 In two studies, COPD patients were found to
benefit from home nebulizer therapy.10,11
The relationship between dyspnea scores and FEV1 ap-
pears to be poor.12,13 Because dynamic compression of the
airways during forced expiration may mask the effects of
bronchodilators on FEV1, we are interested in measuring
inspiratory lung function parameters (ILPs) when dynamic
compression of the bronchi is absent.14e17 We hypothesized
that because of dynamic bronchial compression, the rela-
tionship between the ILPs and dyspnea is more reliable than
the relationship between FEV1 and dyspnea. Our interest in
changes in the ILPs, as measured by changes in the forced
inspiratory volume in 1 s (FIV1), inspiratory capacity (IC),
forced inspiratory flow at 50% of the vital capacity (FIF50)
and peak inspiratory flow (PIF), increased when Taube
et al. determined a more significant correlation between
FIV1 changes and dyspnea using the visual analogue scale
(VAS) (r Z 0.730, p < 0.001) than between the change in
FEV1 and VAS (r Z 0.389, p < 0.01) after administration of
the bronchodilator salbutamol to patients with severe to
very severe COPD.14 Other studies have shown changes in
dyspnea symptoms and in forced inspiratory volumes
following bronchodilator therapy at rest and changes in IC
during exercise.18e24 In our previous study, in subjects with
COPD, we found that the ILPs, FEV1 and VAS score signifi-
cantly improved after bronchodilator inhalation.25 Howev-
er, no studies investigating changes in ILPs and dyspnea
upon bronchodilator administration using different inhaler
delivery devices are currently available. Therefore, our
study aimed to investigate whether ILPs show equal
changes in FEV1 after administering bronchodilators using apMDI and an aerochamber or a nebulizer and whether any
improvement in lung function parameters correlated sig-
nificantly with changes in dyspnea symptoms as measured
by the VAS.Methods
Patients
From January 2007 to August 2007, 41 stable COPD patients
(23 males and 18 females) from our outpatient clinic were
recruited. The subjects had either severe or very severe
COPD (FEV1 < 50% predicted) according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines.26 The inclusion criteria were stable COPD, age of
40e80 years, current or former smoker with more than a 10
pack-year history, and reversibility of FEV1 < 12% of the
predicted normal value and <200 mL.27,28 Stable COPD was
defined as the absence of exacerbations within 2 months
prior to the study, no changes in COPDmedications in the last
8 weeks, no use of oral corticosteroids in the last 2 months
and no use of antibiotics in the last month. Patients on oxy-
gen and patients with allergic rhinitis, asthma, heart dis-
ease, neuromuscular disorders, malignancy or an inability to
respond to the questionnaires were excluded. The medical
ethical commission of ArnhemeNijmegen in the Netherlands
gave permission for this study, and all the patients provided
written informed consent.
Study design
A randomized, crossover trial comparing the two adminis-
tration methods of inhaled Combivent therapy (i.e., a
nebulizer or a pMDI with an aerochamber) was conducted.
The sequence order was determined according to a
computer-generated randomization list. Each subject
participated in the study on two different days within a two-
week period. On each study day, inspiratory and expiratory
spirometric tests with reversibility testing were performed
with Combivent administered using a compressed-air nebu-
lizer (jet nebulizer) or a pMDI.
Pulmonary function testing
All the subjects were asked not to use short-term bron-
chodilators for at least 6 h prior to the study and long-term
bronchodilators for at least 12 h prior to the study. Tio-
tropium and theophylline were not allowed within
24 h prior to spirometric testing.
Table 1 Patient characteristics and baseline lung function
parameters.
Sex, male/female ratio 23/18
Age, years 63  9
Body mass index, kg/m2 25.9  6.2
Height, cm 168  0.09
Weight, kg 73.1  17.4
Smoker former/current, number 16/25
GOLD 3 patients 34
GOLD 4 patients 7
Baseline FEV1, L/s 0.96  0.33
Predicted FEV1, % 35.8  11.5
Baseline FIV1, L/s 2.38  0.74
Baseline IC, L 1.79  0.50
Baseline FIF50, L 4.1  1.5
Baseline PIF, L 4.4  1.5
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quate and acceptable flow volume curves were performed
using standard techniques according to the European Respi-
ratory SocietyandAmericanThoracic Society guidelines.28 For
the predicted FEV1 and forced vital capacity (FVC), the normal
values from the European Community for Steel and Coal were
used.29,30 For the inspiratory parameters, at least five ade-
quate maneuvers were obtained after slow and maximal
expiration.31
Full inspiration was obtained when a plateau in the flow
was reached after at least eight seconds inspiration. The
best of the derived inspiratory parameters were further
analyzed. If the vital capacity (VC) was reached before the
FIV1 during the inspiratory maneuvers, then the FIV1 was
considered to be equal to the VC. The highest FVC, FEV1
and ILP values were recorded. The flow-volume curves were
measured using a V-MAX20 device (Sensor Medics, ViaSys,
Conshohocken, PA, USA).
The inspiratory parameters were obtained as described
previously by Visser et al.31 All of the measurements were
performed by the same person, who also explained the
inhalation technique in detail before the test and moni-
tored the technique carefully. To exclude poor inhalation
technique with the pMDI and aerochamber or nebulizer, the
method of inhalation using each device was standardized.
When using the pMDI and aerochamber, each patient
received two puffs of Combivent aerosol (200 mcg of sal-
butamol and 20 mcg of ipratropium bromide per puff) at the
beginning of a slow inspiration from functional residual
capacity to total lung capacity, followed by a 10-s period of
breath holding. When the De Vilbiss 646 jet nebulizer (2 mL
of Combivent containing 250 mcg of ipratropium bromide
and 2.5 mg of salbutamol per mL) was used, medication
aerosolization was driven by an air compressor at a flow
rate of 5 L/min. The patients breathed tidally through a
mouthpiece until visible aerosol production ceased
(7e8 min). Standardized spirometry tests were performed
before and 45 min after bronchodilator therapy.
Differences in the FEV1 and ILPs after bronchodilation
are expressed as changes in volume (liters) and as percent
changes from the initial value.
To compare the effect of Combivent inhaled using the two
different devices on the ILPs and FEV1, we used the one-hour
repeatability of these lung function parameters, which is the
random variation expressed as coefficients of repeatability.
The patients were classified as responders after inhalation
therapy if the increase was 12% for FEV1, 14% for FIV1,
19% for IC,21% for FIF50 and18% for PIF.32 The response
rate was defined as the percentage of responders.
Prior to the test, all of the subjects were instructed on
the proper use of the VAS. The VAS scores for dyspnea were
recorded after each bronchodilator measurement.13 The
VAS line is a 10-cm-long horizontal line that ranges from 5
to þ5 cm. On the left side, the label represents VAS Z 5
(very much improved). In the middle, VASZ 0 (no change).
To the far right, VAS Z þ5 (much worsened).Definitionofabbreviations:FEV1Z forcedexpiratory volume in
1 s (L/s), FIV1 Z forced inspiratory volume in 1 s (L/s),
ICZ inspiratory capacity (L), FIF50Z forced inspiratory flow at
50% of the vital capacity (L/s), PIFZ peak inspiratory flow (L/s).
Values are given as the mean  SD or number of patients.Statistical analysis
All the results are presented as the mean values  SEM, un-
less otherwise indicated. A paired Student t-test was used toevaluate the differences in all of mean lung function pa-
rameters before and after bronchodilators administration
using each device. The same test was used to compare the
mean changes between the two devices. The response rates
using the various lung function parameters were evaluated
using the McNemar test and Cochran’s Q test.
Wilcoxon’s signed rank test was used to compare VAS
scores between the two devices. Spearman’s correlation
coefficients are given. SPSS for Windows, version 15, was
used for the statistical analysis, and p  0.05 (two-sided)
was defined as statistically significant.
Results
The demographic data and baseline pulmonary function of
the 41 studied patients are presented in Table 1.
Twenty-two patients used the aerochamber device fol-
lowed by the nebulizer device. The other 19 patients used
the devices in the opposite order.
Changes in lung function after bronchodilators
administration using an aerochamber or jet
nebulizer
Changes in the volume (i.e., liters or L/s) and percent
changes from the initial values of the lung function pa-
rameters and VAS scores after inhalation of a standard
bronchodilator using the nebulizer or aerochamber are
presented in Table 2. All of the changes in the lung function
parameters from the pre-intervention values were signifi-
cant (all p  0.004), regardless of which device was used.
Comparing the nebulizer and pMDI, we found a significant
difference in the FEV1 but not in the ILPs. The mean ab-
solute changes in FEV1 were 0.23  0.03 L/s and
0.16  0.02 L/s for the nebulizer and aerochamber,
respectively (pZ 0.004). These changes for FEV1 were also
significant (p Z 0.019) when expressed as percentages.
Table 2 Changes in volume, expressed as absolute values and percent changes from the initial values, and VAS scores,
expressed compared to the baseline values, at 45 min after administering Combivent using a jet nebulizer or pMDI.
Nebulizer Aerochamber
Before (L) After (L) Change (L) Change (%) Before (L) After (L) Change (L) Change (%)
FEV1 0.96  0.05 1.19  0.07 0.23  0.03 23.0  2.5 0.97  0.06 1.13  0.07 0.16  0.02 17.2  2.1
FIV1 2.40  0.12 2.59  0.13 0.20  0.04 9.4  2.2 2.37  0.11 2.61  0.12 0.23  0.04 10.6  1.8
IC 1.81  0.08 2.02  0.10 0.21  0.04 12.2  2.3 1.77  0.08 2.01  0.09 0.23  0.04 13.6  2.3
FIF50 4.05  0.23 4.50  0.25 0.45  0.07 12.7  2.4 4.21  0.23 4.45  0.24 0.25  0.08 7.5  2.3
PIF 4.42  0.24 4.83  0.26 0.41  0.08 10.0  2.1 4.54  0.23 4.85  0.24 0.31  0.07 8.0  2.0
VAS score 1.3 (5, 1) 1.2 (4.2, 0)
Definition of abbreviations: FEV1 Z forced expiratory volume in 1 s (L/s), FIV1 Z forced inspiratory volume in 1 s (L/s),
ICZ inspiratory capacity (L), FIF50Z FIF50 forced inspiratory flow at 50% of the vital capacity (L/s), PIFZ peak inspiratory flow (L/s).
Values are given as the means  SEM. Changes in FEV1, FIV1, and IC are given in liters and FIF50 and PIF in L/s. VAS Z visual analogue
scale; scores given as the means  SEM. The VAS scale ranges from 5 to þ5 cm. A VAS score greater than 0 represents more dyspnea,
VASZ 0 indicates no change in dyspnea and a VAS score less than 0 cm represents an improvement in dyspnea. The data shown are the
means  SEM for lung function parameters and median (range) for the VAS.
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tween the two devices.
Fig. 1 shows all of the mean changes expressed as percent
changes from the baseline. All the mean percent changes in
FEV1 using the nebulizer were significantly greater
(p  0.003) than the mean changes in the ILPs, and the same
pattern was observed for the aerochamber, except for the
comparison between the mean FEV1 change and the mean IC
change (p Z 0.19).
ILPs response after bronchodilators administration
using a nebulizer or aerochamber
The percentages of participants who had a response after
using the aerochamber, as measured by the FIV1, IC, FIF50,
PIF and FEV1, were 37%, 39%, 17%, 17% and 54%, respec-
tively. The corresponding percentages for the nebulizer
therapy were 27%, 29%, 20%, 27% and 63%, respectively.
None of these percentages of responders differed signifi-
cantly between the aerochamber and nebulizer (all
p > 0.38).0.0
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Figure 1 Mean changes in FEV1, FIV1, IC, FIF50 and PIF after
bronchodilation using an aerochamber device (closed symbols)
or nebulizer device (open symbols). Error bars represent SEM. P
values for the differences between the two devices are shown
at the bottom.When the nebulizer was used, the number of responders
according to the FEV1 was significantly higher compared to
those measured using all of the ILPs (p < 0.001); however,
among the various ILPs, we found no differences in the
number of responders (p Z 0.71). When the aerochamber
was used, we found more responders when measuring the
FEV1 than when measuring the FIF50 or PIF (both p < 0.001).
Relationship between dyspnea and changes in the
ILPs after bronchodilators administration using
different devices
Sixty-eight percent (28 of 41 patients) of the patients re-
ported a decrease in dyspnea (VAS < 0) after nebulizer
therapy, whereas 63% (26 of 41 patients) reported a decrease
after aerochamber therapy. The mean VAS score did not
significantly differ between the two devices (p Z 0.33).
There were significant and moderate correlations between
the change in the VAS score and the change in the FIF50
(rZ 0.48, pZ 0.001) and between the VAS score and PIF
(rZ0.54, p< 0.001) after use of the nebulizer (Fig. 2). No
other significant correlations, including those between the
VAS score and the FIF50 (rZ 0.02, pZ 0.88) or PIF (rZ 0.02,
pZ 0.46),were found. ThemeanVAS score after using either
device was significantly less than zero (p < 0.001).Discussion
This study aimed to investigate whether the ILPs of COPD
patients show similar changes to the FEV1 after inhalation of
bronchodilators using either a nebulizer or an aerochamber.
The main findings of this study are that all of the ILP
values and FEV1 improved significantly from baseline after
Combivent administration using a nebulizer or aerochamber
(p  0.004), but none of the changes in the ILPs differed
between the devices. When a nebulizer was used, the
change in FEV1 was significantly greater than the change in
FEV1 observed when an aerochamber was used. We also
found significant correlations between the lung function
parameters FIF50 and PIF and the VAS score when a
Figure 2 Changes in FIF50 (circles) and PIF (squares) after
nebulizer therapy, expressed as the percent changes from
baseline and plotted versus the VAS dyspnea scores. The lines
represent least-squares regression lines (solid line: FIF50; dotted
line: PIF).
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significant correlations were found between the ILPs and
FEV1 versus VAS. These findings may indicate that treat-
ment of COPD patients using a nebulizer yields better re-
sults than treatment using an aerochamber. Currently,
there is no literature available regarding changes over the
short term or long term to compare or support these find-
ings. In our previous study, in contrast to the study by Taube
et al., the mean VAS score was not significantly correlated
with the FEV1 or ILPs after bronchodilator therapy.
14,25 This
discrepancy could result from the different populations of
COPD subjects used in each study. Our former study
included subjects from all of the GOLD categories; in the
present study, only GOLD stages three and four were
included. Although we used the same VAS scale and similar
patients as the study by Taube et al.,14 our results here also
differ from their findings, corroborating our previous
report. The significantly greater increase in FEV1 after
treatment with a nebulizer versus an aerochamber may be
the result of differences in particle size and airway depo-
sition, differences in the dose-effect relationship of Com-
bivent when delivered using the two devices, differences in
the inhalation technique used with the devices or differ-
ences in the electrostatic charge of the spacer.33e35
Regarding the differences in the dose-effect relationship
of bronchodilators delivered by the two devices, in our
study, there was a substantial difference in the nominal
doses of the bronchodilators administered with pMDI plus
spacer (lower dose Combivent) and the nebulizer (higher
dose), and this may have caused a favorable higher change
in FEV1 for the nebulizer. The literature reveals that pMDI
delivers 10e20% of effective drug deposition in the lower
airways; this value is 20e30% for pMDI plus spacer and
approximately 10% for a nebulizer. Therefore, for nebu-
lizers, larger doses need to be administered to compensate
for the lower drug deposition. The difference between the
nebulizer and pMDI plus spacer is compensated for by using4e6 times more dose for the nebulizer compared with
pMDI.36,37 The observed changes in the ILPs and FEV1 from
baseline after bronchodilation using either device are
consistentwith our previous study.25 Among the ILPs, greater
changes in the IC and FIF50 were observed after nebulizer
therapy. However, greater changes in the IC and FIV1 were
observed after aerochamber therapy. Both devices provided
noteworthy changes in the IC, possibly because the IC
generally increases after bronchodilator therapy, which
implies a reduction in hyperinflation. This conclusion is
supported by the findings of Newton et al., who showed
greater IC changes after bronchodilator therapy in COPD
subjects with severe hyperinflation.16 Because all the sub-
jects in this study had COPD with GOLD stage three or four,
they may have had more severe hyperinflation and thus
shown greater increases in IC after bronchodilator ther-
apy.38,39 The notable increase in the IC may have also been
the result of a decreased baseline IC, as documented by Di
Marco et al., who found greater increases in IC after bron-
chodilator therapy in 20 COPD patients (predicted FEV1%
52  3) with a decreased baseline IC.40
Our study is the first in which reversibility of ILPs after
combined bronchodilator therapy (i.e., treatment with an
anticholinergic agent and a beta-agonist) using different
inhaler devices was investigated. In addition to our previ-
ously described study, four studies by Taube et al. and
three studies by O’Donnell et al., all of which used COPD
patients as subjects, are the only studies in which ILP
changes after bronchodilator therapy were inves-
tigated.14,18e24 However, in these studies, the effect of the
devices on the reversibility testing of bronchodilators was
not investigated sufficiently. The mean mass aerosol
diameter, which is a measure of inhaled particle diameter,
may have a greater effect on the degree of penetration into
the lower airways and distribution patterns when using a
pMDI compared to a nebulizer. Thus, we eliminated dif-
ferences in the effective deposition of particles based on
size by using an aerochamber when Combivent was deliv-
ered using a pMDI.35 In one study, Taube et al. administered
400 mcg of salbutamol through a metered-dose inhaler
using an inhalation chamber, but the specific type was not
mentioned.14 In another study, they administered 200 mcg
of salbutamol using a pMDI without a spacer.19 In a third
study, fenoterol was administered via a pMDI without a
spacer, and its efficacy was compared to that of 200 mcg of
oxitropiumbromide.18 Finally, in a fourth study, 24 mcg of
inhaled formoterol (two puffs of Oxis delivered by Tur-
buhaler) was used.20 O’Donnell and colleagues adminis-
tered 200 mcg of salbutamol through a pMDI without a
spacer, 18 mcg of tiotropium using a hand inhaler and
500 mcg of ipratropium bromide using a nebulizer.22e24
Because anticholinergic drugs and beta-agonists cause
bronchodilation by various mechanisms and because we
wanted to achieve the maximal effect of the inhaled
bronchodilator on the ILPs, we used Combivent, which is a
standardized combination of salbutamol and ipratropium
bromide. Our study is the first in which the effect of com-
bined anticholinergic and beta-agonist drugs was tested. In
our previously mentioned study, we investigated the effect
of four puffs of 100 mcg of salbutamol and four puffs of
20 mcg of ipratropium bromide when delivered separately
using an Aerochamber Plus. Overall, when Combivent was
1398 S.K. Ramlal et al.delivered using the Aerochamber Plus (in the present
study), greater changes in the ILPs and FEV1 were observed
than when each bronchodilator was administered sepa-
rately (in a previous study).25
In conclusion, in this study, we investigated whether the
effect of inhalation of Combivent using different inhaler
devices (i.e., a nebulizer or aerochamber) on ILPs in subjects
with COPD (GOLD stages three and four) was the same as the
effect on the FEV1. The changes in the ILPs did not differ
between the devices, but greater and more significant
changes were found for FEV1 when using a nebulizer. Addi-
tionally, unlike treatment with an aerochamber, nebulizer
therapy resulted in significant correlations between the VAS
and FIF50 and the VAS and PIF. However, overall, there is no
clear-cut advantage for the lowernominal dose of Combivent
withpMDI plus spacer comparedwith thehigher nominal dose
of Combivent with the nebulizer. An implication of these
findings could be that in stable COPD patients, we suggest
that pMDI plus spacer be used rather than the nebulizer
because of its rapid and convenient dosing, and it is cheaper,
safe, portable and easier to use.Conflict of interest
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